<span item_type="fundamental" item_id="4d17d4c89d2a387fd55ee01476fcdd62" counter_id="ST/US/ACONW" env="prod"></span><span item_type="announcement" item_id="516341159447303297" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 18.99 K.</p><p>EPS: As of FY2025 Q1, the actual value is USD -9.32.</p><p></p><h3>Segment Revenue</h3><ul><li>Total revenue for the quarter ended March 31, 2025, was $18,991, an increase of $8,877, or 88%, from $10,114 for the quarter ended March 31, 2024. This increase was driven primarily by additional patient-pay scans at Radnet facilities utilizing NOCISCAN® reports.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1635077/000168316825003594/aclarion_i10q-033125.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Gross Profit (Loss)</strong>: The gross loss for the quarter ended March 31, 2025, was -$4,488, compared to -$9,362 for the same period in 2024, showing an improvement of $4,874.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1635077/000168316825003594/aclarion_i10q-033125.htm"></span></li><li><strong>Operating Expenses</strong>: Total operating expenses increased to $1,487,437 for the quarter ended March 31, 2025, from $1,265,945 for the same period in 2024, an increase of $221,492.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1635077/000168316825003594/aclarion_i10q-033125.htm"></span></li><li><strong>Net Loss</strong>: The net loss for the quarter ended March 31, 2025, was -$2,037,436, compared to -$2,399,102 for the same period in 2024, showing a reduction in loss by $361,665.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1635077/000168316825003594/aclarion_i10q-033125.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Cash used in operating activities was -$2,510,782 for the three months ended March 31, 2025, compared to -$2,238,557 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1635077/000168316825003594/aclarion_i10q-033125.htm"></span></li><li><strong>Financing Activities</strong>: The company raised $16,885,681 through financing activities during the three months ended March 31, 2025, compared to $3,413,780 in the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1635077/000168316825003594/aclarion_i10q-033125.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue its focus on the development and commercialization of its NOCISCAN® reports, leveraging recent capital raises to fund operations into the third quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1635077/000168316825003594/aclarion_i10q-033125.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Warrant and Derivative Liabilities</strong>: The company recorded a favorable adjustment in the fair value of warrant and derivative liabilities of $11,721 for the quarter ended March 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1635077/000168316825003594/aclarion_i10q-033125.htm"></span></li></ul>

ACLARION INC C/WTS 21/04/2027 (TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 18.99 K